United States
Search    
Include All CSL Behring Country Sites

RiaSTAP ®

Fibrinogen Concentrate (Human)
Full Prescribing Information for RiaSTAP®        Important Safety Information

RiaSTAP is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (CFD), including afibrinogenemia and hypofibrinogenemia.

RiaSTAP is not indicated for dysfibrinogenemia.

  • Concentrated lyophilized protein that is easily reconstituted
  • Labeled with exact fibrinogen content to assist with coagulation management
  • Demonstrated ability to effectively raise fibrinogen to within target levels
  • Concentrated fibrinogen allows for low infusion volume
  • Virus inactivation/removal reduces risk of exposure to infectious agents
  • Easily stored and accessed when needed, due to room temperature storage and 30-month shelf life

Visit www.riastap.comto learn more.

Diagnostic Codes (ICD-10-CM)

Billing Codes (HCPCS, NDC, CPT)

Medicare Part B ASP Pricing Limits

Authorized Distributors

Important Safety Information for RiaSTAP

RiaSTAP®, Fibrinogen Concentrate (Human), is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

RiaSTAP is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products.

Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment. Thrombotic events have been reported in patients receiving RiaSTAP; weigh the benefits of administration versus the risks of thrombosis.

RiaSTAP is made from pooled human plasma. Products made from human plasma may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most serious adverse reactions observed are thrombotic episodes (pulmonary embolism, myocardial infarction, deep vein thrombosis) and anaphylactic reactions. The most common adverse reactions observed in clinical studies (frequency >1%) were fever and headache.

Please see full prescribing information for RiaSTAP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


CRP16-05-0001 05/2016
© 2017 CSL Behring